American Diabetes Association 79th Scientific Sessions

June 7-11, 2019; San Francisco, CA; Resource Hub

Welcome to our ADA 2019 resource hub! This is a one-stop shop for all your ADA 2019 needs. We'll post all of our ADA-related documents as we publish them, so check back often.

Top Abstracts

Day by Day Coverage

Diabetes Therapy Highlights

Diabetes Technology Highlights

Category Documents

The links below will go live as we publish each document leading up to ADA. For more on how to best use this resource, see our Category Document Tip Sheet. Please note that all abstracts, even when available on the ADA itinerary planner (5 pm EDT on Tuesday, June 4), are still under embargo. See the full ADA embargo policy here.

  • Diabetes Technology:
  • Diabetes Therapy:
    • SGLT InhibitorsSGLT-2s, SGLT-1s, relevant combination therapies, and investigational indications.
    • GLP-1 AgonistsGLP-1s and relevant combination therapies.
    • InsulinInsulin (injectable, oral, and inhaled) and relevant combination therapies.
    • Novel TherapiesNew drug classes under investigation for diabetes, obesity, or related conditions. Includes novel glucagon formulations and dual agonists (e.g. GLP-1/glucagon). Does NOT include new products within drug classes that are currently available, including insulin, GLP-1 agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, but does include combinations of these classes with new therapeutic targets (again, e.g. GLP-1/glucagon). 
    • DPP-4 InhibitorsDPP-4s and relevant combination therapies.
  • Other:
    • Beyond A1c and HypoglycemiaGlycemic outcomes beyond A1c (time-in-ranges, glycemic variability), patient-reported outcomes, hypoglycemia.  
    • Type 1 "Cure" Therapies, Adjuncts, and PathophysiologyCure-based topics and pathophysiology of type 1 diabetes, including predictors of the disease, prevention, and clinical data on cell-based therapies. This category also includes adjunct therapies for type 1 diabetes.
    • Obesity, Prediabetes, and RemissionObesity therapies, bariatric surgery, prediabetes care, diabetes prevention, and efforts to reverse type 2 diabetes.
    • Policy, Reimbursement, and EducationModels of care delivery for diabetes, treatment guidelines and algorithms, big picture information on the state of diabetes and diabetes care in the US and globally. Also includes select abstracts related to diabetes education and psychosocial support.
    • Diabetes ComplicationsA curated collection of abstracts on diabetes complications, weighted towards nephropathy, retinopathy, and macrovascular disease. 
    • NAFLD/NASH: Includes all abstracts related to the treatment of fatty liver disease.

Things to Do in San Francisco